Trillium Therapeutics Inc (TRIL):製薬・医療:M&Aディール及び事業提携情報

【英語タイトル】Trillium Therapeutics Inc (TRIL) - Pharmaceuticals & Healthcare - Deals and Alliances Profile

GlobalDataが出版した調査資料(DATA904C9805)・商品コード:DATA904C9805
・発行会社(調査会社):GlobalData
・発行日:2018年11月
・ページ数:47
・レポート言語:英語
・レポート形式:PDF
・納品方法:Eメール
・産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD250 ⇒換算¥27,750見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD500 ⇒換算¥55,500見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD750 ⇒換算¥83,250見積依頼/購入/質問フォーム
販売価格オプションの説明
※お支払金額:換算金額(日本円)+消費税
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000を加算
※納期:即日〜2営業日(3日以上かかる場合は別途表記又はご連絡)
※お支払方法:納品日+5日以内に請求書を発行・郵送(請求書発行日より2ヶ月以内に銀行振込、振込先:三菱UFJ銀行/H&Iグローバルリサーチ株式会社、支払期限と方法は調整可能)
【レポートの概要】

Summary
Trillium Therapeutics Inc (Trillium), formerly Neurogenesis Biotech Corp, is a clinical stage immuno-oncology company, which develops novel therapies for the treatment of cancer. The company’s lead program, TTI-621, a SIRPaFc fusion protein is being developed for hematological malignancies. Its second SIRPaFc fusion protein, TTI-622, is primarily being developed for combination therapy. Trillium has developed a proprietary medicinal chemistry platform that is used for the creation of new chemical entities with improved pharmacological properties from validated drugs and drug candidates. The company utilizing this platform is also developing bromodomain inhibitor and epidermal growth factor receptor antagonist. Trillium is headquartered in Mississauga, Ontario, Canada.

Trillium Therapeutics Inc (TRIL) – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 5
List of Figures 5
Trillium Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Trillium Therapeutics Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7
Trillium Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Trillium Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9
Trillium Therapeutics Inc, Medical Devices Deals, 2012 to YTD 2018 10
Trillium Therapeutics Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 11
Trillium Therapeutics Inc, Pharmaceuticals & Healthcare, Deal Details 12
Venture Financing 12
Fluorinov Pharma Raises US$1.5 Million In Venture Financing 12
Merger 13
Stem Cell Therapeutics Completes Merger With Trillium Therapeutics 13
Licensing Agreements 14
Trillium Therapeutics Amends Licensing Agreement with University Health Network 14
Stem Cell Therapeutics Enters Into Licensing Agreement With MaRS Innovation For Cancer Stem Cell Program 16
StemCell Technologies Enters Into Licensing Agreement With HUB Foundation for Organoid Technology 18
Stem Cell Therapeutics Enters Into Option For Licensing Agreement With University Of Toronto 19
Stem Cell Therapeutics Enters Into Option For Licensing Agreement With University of York For Prostate Cancer Stem Cell Assets 21
StemCell Technologies Enters Into Licensing Agreement With iPS Academia Japan For Induced Pluripotent Stem Cell Technologies 22
Equity Offering 23
Trillium Therapeutics Files Shelf Prospectus to Raise up to USD150 Million 23
Trillium Therapeutics Raises USD20 Million in Private Placement of Shares 24
Trillium Therapeutics Completes Underwriters’ Partial Exercise of Over-Allotment Option of Public Offering of Shares and Prefererd Shares for USD31 Million 25
Trillium Therapeutics Raises USD55.2 Million in Public Offering of Shares 27
Stem Cell Therapeutics Completes Private Placement Of Shares For US$31 Million 28
Stem Cell Therapeutics Completes Public Offering Of Units For US$3.2 Million 30
Acquisition 31
Trillium Therapeutics Acquires Fluorinov Pharma 31
Trillium Therapeutics Inc – Key Competitors 32
Trillium Therapeutics Inc – Key Employees 33
Trillium Therapeutics Inc – Locations And Subsidiaries 34
Head Office 34
Other Locations & Subsidiaries 34
Recent Developments 35
Financial Announcements 35
Aug 08, 2018: Trillium Therapeutics reports second quarter 2018 financial and operating results 35
May 11, 2018: Trillium Therapeutics Reports First Quarter 2018 Financial and Operating Results 36
Mar 09, 2018: Trillium Therapeutics Reports Annual 2017 Financial And Operating Results 37
Nov 10, 2017: Trillium Therapeutics Reports Third Quarter 2017 Financial and Operating Results 38
Aug 11, 2017: Trillium Therapeutics Reports Second Quarter 2017 Financial and Operating Results 39
May 12, 2017: Trillium Reports First Quarter 2017 Financial and Operating Results 40
Mar 10, 2017: Trillium Therapeutics Reports Annual 2016 Financial and Operating Results 41
Corporate Communications 42
Jun 07, 2018: Trillium Therapeutics Appoints Yaping Shou, MD, PhD as Chief Medical Officer 42
Product News 43
07/05/2017: Trillium Provides Update on TTI-2341 EGFR Inhibitor Program 43
04/10/2018: Trillium Therapeutics Provides Update on TTI-622 Program 44
Clinical Trials 45
Nov 20, 2017: Trillium Therapeutics TTI-2341 EGFR Inhibitor Program Featured at the Society for Neuro-Oncology 22nd Annual Meeting 45
Feb 02, 2017: Trillium Therapeutics Provides Update On TTI-622 46
Appendix 47
Methodology 47
About GlobalData 47
Contact Us 47
Disclaimer 47

List of Tables
Trillium Therapeutics Inc, Pharmaceuticals & Healthcare, Key Facts, 2017 2
Trillium Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Trillium Therapeutics Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7
Trillium Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Trillium Therapeutics Inc, Deals By Therapy Area, 2012 to YTD 2018 9
Trillium Therapeutics Inc, Medical Devices Deals, 2012 to YTD 2018 10
Trillium Therapeutics Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 11
Fluorinov Pharma Raises US$1.5 Million In Venture Financing 12
Stem Cell Therapeutics Completes Merger With Trillium Therapeutics 13
Trillium Therapeutics Amends Licensing Agreement with University Health Network 14
Stem Cell Therapeutics Enters Into Licensing Agreement With MaRS Innovation For Cancer Stem Cell Program 16
StemCell Technologies Enters Into Licensing Agreement With HUB Foundation for Organoid Technology 18
Stem Cell Therapeutics Enters Into Option For Licensing Agreement With University Of Toronto 19
Stem Cell Therapeutics Enters Into Option For Licensing Agreement With University of York For Prostate Cancer Stem Cell Assets 21
StemCell Technologies Enters Into Licensing Agreement With iPS Academia Japan For Induced Pluripotent Stem Cell Technologies 22
Trillium Therapeutics Files Shelf Prospectus to Raise up to USD150 Million 23
Trillium Therapeutics Raises USD20 Million in Private Placement of Shares 24
Trillium Therapeutics Completes Underwriters' Partial Exercise of Over-Allotment Option of Public Offering of Shares and Prefererd Shares for USD31 Million 25
Trillium Therapeutics Raises USD55.2 Million in Public Offering of Shares 27
Stem Cell Therapeutics Completes Private Placement Of Shares For US$31 Million 28
Stem Cell Therapeutics Completes Public Offering Of Units For US$3.2 Million 30
Trillium Therapeutics Acquires Fluorinov Pharma 31
Trillium Therapeutics Inc, Key Competitors 32
Trillium Therapeutics Inc, Key Employees 33
Trillium Therapeutics Inc, Subsidiaries 34

List of Figures
Trillium Therapeutics Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
Trillium Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
Trillium Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2
Trillium Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
Trillium Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Trillium Therapeutics Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 7
Trillium Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Trillium Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9
Trillium Therapeutics Inc, Medical Devices Deals, 2012 to YTD 2018 10

★調査レポート[Trillium Therapeutics Inc (TRIL):製薬・医療:M&Aディール及び事業提携情報] (コード:DATA904C9805)販売に関する免責事項を必ずご確認ください。
★調査レポート[Trillium Therapeutics Inc (TRIL):製薬・医療:M&Aディール及び事業提携情報]についてメールでお問い合わせ


◆H&Iグローバルリサーチのお客様(例)◆